Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses

[1]  Yuzong Chen,et al.  DrugMAP: molecular atlas and pharma-information of all drugs , 2022, Nucleic Acids Res..

[2]  M. Bhattacharya,et al.  Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective , 2022, Vaccines.

[3]  Jerome H. Kim,et al.  Leveraging lessons learned from the COVID-19 pandemic for HIV , 2022, Communications Medicine.

[4]  T. Tenson,et al.  DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs) , 2022, Nucleic Acids Res..

[5]  R. Baric,et al.  Stopping pandemics before they start: Lessons learned from SARS-CoV-2 , 2022, Science.

[6]  C. Chakraborty,et al.  Editorial overview: An initiative toward Ebolavirus disease (EVD) free world: An edited special anti-infective issue on Ebola virus disease , 2022, Current Opinion in Pharmacology.

[7]  C. Chakraborty,et al.  The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies , 2021, Frontiers in Pharmacology.

[8]  C. Chakraborty.  Therapeutics development for Ebola virus disease: A recent scenario. , 2021, Current opinion in pharmacology.

[9]  V. Uversky,et al.  Interface‐based design of the favipiravir‐binding site in SARS‐CoV‐2 RNA‐dependent RNA polymerase reveals mutations conferring resistance to chain termination , 2021, FEBS letters.

[10]  Mina T. Kelleni.  Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment , 2021, SN Comprehensive Clinical Medicine.

[11]  M. Arab-Zozani,et al.  The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials , 2021, Scientific Reports.

[12]  D. Barford,et al.  Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP , 2021, Proceedings of the National Academy of Sciences.

[13]  D. Tegunov,et al.  Mechanism of SARS-CoV-2 polymerase stalling by remdesivir , 2021, Nature communications.

[14]  Ashish Ranjan Sharma,et al.  SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development , 2021, Expert review of clinical pharmacology.

[15]  David W. Taylor,et al.  Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication , 2020, bioRxiv.

[16]  C. Caracta,et al.  Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial , 2020, International Journal of Infectious Diseases.

[17]  Wing‐Fu Lai,et al.  Tackling COVID‐19 Using Remdesivir and Favipiravir as Therapeutic Options , 2020, Chembiochem.

[18]  T. Soluyanova,et al.  Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19 , 2020, SSRN Electronic Journal.

[19]  J. Qi,et al.  Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir , 2020, bioRxiv.

[20]  Wing‐Fu Lai,et al.  Tackling COVID‐19 Using Remdesivir and Favipiravir as Therapeutic Options , 2020, Chembiochem : a European journal of chemical biology.

[21]  J. Wen,et al.  Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series , 2020, Critical Care.

[22]  S. Tajima,et al.  A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[23]  H. Xu,et al.  RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19 , 2020, Biochemical and Biophysical Research Communications.

[24]  U. Agrawal,et al.  Favipiravir: A new and emerging antiviral option in COVID-19 , 2020, Medical Journal Armed Forces India.

[25]  Ashish Ranjan Sharma,et al.  Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 , 2020, Frontiers in Pharmacology.

[26]  Ashish Ranjan Sharma,et al.  COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients , 2020, Journal of medical virology.

[27]  Ashish Ranjan Sharma,et al.  Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19 , 2020, Archives of Medical Research.

[28]  E. Coomes,et al.  Favipiravir, an antiviral for COVID-19? , 2020, The Journal of antimicrobial chemotherapy.

[29]  F. Costanzo,et al.  Use of subcutaneous tocilizumab in patients with COVID‐19 pneumonia , 2020, Journal of medical virology.

[30]  Ashish Ranjan Sharma,et al.  Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More , 2020, Archives of Medical Research.

[31]  F. Buonaguro,et al.  SARS-CoV-2 RNA polymerase as target for antiviral therapy , 2020, Journal of Translational Medicine.

[32]  M. V. Cicinelli,et al.  COVID-19 pandemic: Lessons learned and future directions , 2020, Indian journal of ophthalmology.

[33]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[34]  Yan Zhang,et al.  Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir , 2020, bioRxiv.

[35]  C. Chakraborty,et al.  SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. , 2020, European review for medical and pharmacological sciences.

[36]  T. Daikoku,et al.  Favipiravir, an anti-influenza drug against life-threatening RNA virus infections , 2020, Pharmacology & Therapeutics.

[37]  R. Goldstein,et al.  Mutagenesis in Norovirus in Response to Favipiravir Treatment. , 2018, The New England journal of medicine.

[38]  Karel Berka,et al.  MOLEonline: a web-based tool for analyzing channels, tunnels and pores (2018 update) , 2018, Nucleic Acids Res..

[39]  Radka Svobodová Vařeková,et al.  PDBsum: Structural summaries of PDB entries , 2017, Protein science : a publication of the Protein Society.

[40]  Kenneth O. Logan,et al.  Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Y. Furuta,et al.  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[42]  Ivet Bahar,et al.  DynOmics: dynamics of structural proteome and beyond , 2017, Nucleic Acids Res..

[43]  P. Lemey,et al.  Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis , 2016, Antimicrobial Agents and Chemotherapy.

[44]  P. Maes,et al.  Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea , 2016, PLoS medicine.

[45]  R. Siva,et al.  Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus , 2016, Infectious Diseases of Poverty.

[46]  C. Chakraborty,et al.  Ebola eradication may need wider partnership , 2014, Canadian Medical Association Journal.

[47]  D. Smee,et al.  Favipiravir (T-705), a novel viral RNA polymerase inhibitor. , 2013, Antiviral research.

[48]  J. Neyts,et al.  Favipiravir (T-705) inhibits in vitro norovirus replication. , 2012, Biochemical and biophysical research communications.

[49]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[50]  Yoshihiro Kawaoka,et al.  T-705 (favipiravir) activity against lethal H5N1 influenza A viruses , 2009, Proceedings of the National Academy of Sciences.

[51]  D. Smee,et al.  Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice , 2006, Antimicrobial Agents and Chemotherapy.

[52]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[53]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[54]  Haruki Nakamura,et al.  Protein Data Bank (PDB): The Single Global Macromolecular Structure Archive. , 2017, Methods in molecular biology.

[55]  M. Kurokawa,et al.  T-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug. , 2017, Acta virologica.

[56]  Matthew L. Danielson,et al.  Computer-aided drug design platform using PyMOL , 2011, J. Comput. Aided Mol. Des..

[57]  Thomas A. Henzinger,et al.  INTERFACE-BASED DESIGN , 2005 .